Symptomatic methemoglobinemia in a patient with metastatic clear cell renal cell carcinoma treated with pembrolizumab and axitinib combination therapy: a case report

BACKGROUND: Combination regimens that include immune checkpoint (ICI) and vascular endothelial growth factor (VEGF) inhibition have opened the door to new treatment opportunities for patients with metastatic renal cell carcinoma (mRCC). While these treatment options have provided improved tolerabili...

Descripción completa

Detalles Bibliográficos
Autores principales: Olsen, T. Anders, Martini, Dylan J., Evans, Sean T., Goldman, Jamie M., Bilen, Mehmet Asim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7893948/
https://www.ncbi.nlm.nih.gov/pubmed/33602288
http://dx.doi.org/10.1186/s13256-020-02637-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7893948/
https://www.ncbi.nlm.nih.gov/pubmed/33602288
http://dx.doi.org/10.1186/s13256-020-02637-w

Ejemplares similares